FDA hands BeOne, Taiho approvals for blood cancers

Pharmaphorum

BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.

pharminent May 14, 2026 (Last updated: May 21, 2026)

Pharmaphorum

BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho’s Inqovi has acute myeloid leukaemia added to its label.

Related Stories